|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||108.14 - 109.27|
|52-week range||61.95 - 129.79|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||36.15|
|Forward dividend & yield||1.51 (2.31%)|
|Ex-dividend date||28 Sept 2020|
|1y target est||114.29|
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.
(Bloomberg) -- Biogen Inc. shares surged after its controversial Alzheimer’s disease therapy was approved by U.S. regulators, a landmark decision that stands to dramatically change treatment for the debilitating brain condition.The stock gained as much as 64% shortly after the news of the clearance, triggering a brief volatility halt. It ended up 38% at $395.85, the biggest single-day gain since drug officials first said that the treatment appeared effective in November.The Food and Drug Adminis